Lung Cancer Trials Ask AI to find trials
Active Not RecruitingNot applicableNCT05644808
Official study title

MYLUNG Consortium Study Protocol 2

Study summary

This pragmatic study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 18, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Not applicable

Observational

Where is it offered?18 U.S. locations

Locations may change over time.

Who runs it?US Oncology Research

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
US Oncology Research
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Early-stage or resectable→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Adult subjects (18 years and older) with newly diagnosed early stage, locally advanced or metastatic non-small cell lung cancer
  • Eligible for systemic therapy based on the treating provider's assessment
  • Subjects who developed locally advanced or metastatic disease after receiving adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of locally advanced or metastatic disease
  • Subjects may be enrolled within 30 days of initiation of systemic therapy
  • Signed informed consent
Reasons someone may not be able to joinExclusion criteria
  • Stage IA at the time of enrollment
  • Subjects with small cell lung cancer
  • Subjects with Unknown primary tumor origin

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Southern Cancer Center, PCDaphne, Alabama
  • Rocky Mountain Cancer CenterDenver, Colorado
  • Woodlands Medical Specialists, PAPensacola, Florida
  • Illinois Cancer SpecialistsNiles, Illinois
  • Maryland Oncology Hematology, P.A.Silver Spring, Maryland
  • Minnesota Oncology Hematology, P.A.Minneapolis, Minnesota
  • New York Oncology Hematology, P.C.Albany, New York
  • Oncology Hematology Care Clinical Trials, LLCCincinnati, Ohio
  • Willamette Valley Cancer Institute and Research CenterEugene, Oregon
  • Texas Oncology - West TexasAbilene, Texas
  • Texas Oncology- DFWWArlington, Texas
  • Texas Oncology-Dallas Presbyterian HospitalDallas, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 18, 2026. Always confirm current availability with the study team.

View original record ↗